Saying you will be running clinical trials is one of those things you put in a paper to make it sound more exciting and have it published in high impact journal. Not so much a lie, but an aspiration.
I can say for certain that the reason that COH hasn’t asked for GMP Bisantrene has nothing to do with the IP licensing agreement.
I can also tell you from bitter experience that citations have little impact on grant funding. I am not alone in this and many, many fantastic discoveries never make it into the clinic that should.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-153
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |